Ramino Bio

Ramino Bio is dedicated to the development of an oral drug for treating metabolic diseases. Our innovative lead compound can address the needs of patients suffering from various metabolic diseases, including the rare genetic disease MSUD. Our innovative technology in the branched-chain amino acid (BCAA) catabolism field is setting new standards, and we are expanding our expertise to tackle T2D comorbidities as well. At Ramino Bio, our top priority is “Patients above all”, and we are open to exploring collaboration or partnership opportunities to achieve better outcomes for their benefit.